Neofordex 40 mg (dexamethasone): removal of the score-line and the associated 20 mg posology
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Neofordex
|
| Active substance |
dexamethasone
|
| Therapeutic area (MeSH) |
Multiple Myeloma
|
| Procedure number |
EMEA/H/C/004071/II/0017-G
|
| Regulatory outcome |
Variation
|
| DHPC type |
Change in dosing recommendation
|
| Human ATC code |
H02AB02
|
| Dissemination date |
17/02/2023
|